Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
KZR

KZR - Kezar Life Sciences Inc Stock Price, Fair Value and News

0.69USD-0.02 (-2.82%)Delayed as of 13 Jun 2024, 01:00 pm ET

Market Summary

KZR
USD0.69-0.02
Delayedas of 13 Jun 2024, 01:00 pm
-2.82%

KZR Stock Price

View Fullscreen

KZR RSI Chart

KZR Valuation

Market Cap

51.7M

Price/Earnings (Trailing)

-0.51

Price/Sales (Trailing)

7.38

Price/Free Cashflow

-0.61

KZR Price/Sales (Trailing)

KZR Profitability

Return on Equity

-59.92%

Return on Assets

-50.89%

Free Cashflow Yield

-164.75%

KZR Fundamentals

KZR Revenue

Revenue (TTM)

7.0M

Rev. Growth (Qtr)

-100%

KZR Earnings

Earnings (TTM)

-101.3M

Earnings Growth (Yr)

2.44%

Earnings Growth (Qtr)

32.86%

Breaking Down KZR Revenue

52 Week Range

0.682.69
(Low)(High)

Last 7 days

1.4%

Last 30 days

-5.3%

Last 90 days

-16.5%

Trailing 12 Months

-73.3%

How does KZR drawdown profile look like?

KZR Financial Health

Current Ratio

11.49

Debt/Equity

0.05

Debt/Cashflow

-9.47

KZR Investor Care

Shares Dilution (1Y)

0.54%

Diluted EPS (TTM)

-1.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230007.0M

Tracking the Latest Insider Buys and Sells of Kezar Life Sciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Aug 15, 2023
morningside venture investments ltd
gifted
-
-
-3,500,000
-
Jul 20, 2023
kirk christopher j.
acquired
44,055
0.9
48,950
-
Feb 06, 2023
morningside venture investments ltd
sold
-275,320
6.883
-40,000
-
Feb 03, 2023
morningside venture investments ltd
sold
-178,650
7.146
-25,000
-
Feb 02, 2023
morningside venture investments ltd
sold
-359,500
7.19
-50,000
-
Feb 01, 2023
morningside venture investments ltd
sold
-278,000
6.95
-40,000
-
Jan 31, 2023
morningside venture investments ltd
sold
-212,400
7.08
-30,000
-
Jan 30, 2023
morningside venture investments ltd
sold
-207,300
6.91
-30,000
-
Jan 25, 2023
morningside venture investments ltd
sold
-342,500
6.85
-50,000
-
Jan 24, 2023
morningside venture investments ltd
sold
-558,400
6.98
-80,000
-

1–10 of 50

Which funds bought or sold KZR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
new
-
20,000
20,000
-%
May 17, 2024
Ikarian Capital, LLC
added
1.83
-25,019
783,484
0.09%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-64.61
-43,629
22,151
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
sold off
-100
-11,129
-
-%
May 15, 2024
Tower Research Capital LLC (TRC)
reduced
-43.09
-4,979
5,893
-%
May 15, 2024
DEUTSCHE BANK AG\
unchanged
-
-13,963
251,339
-%
May 15, 2024
STATE STREET CORP
added
0.69
-44,153
1,013,200
-%
May 15, 2024
MORGAN STANLEY
reduced
-60.99
-154,446
91,198
-%
May 15, 2024
JACOBS LEVY EQUITY MANAGEMENT, INC
reduced
-94.52
-871,789
47,980
-%
May 15, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
2.86
-1,000
43,000
-%

1–10 of 48

Are Funds Buying or Selling KZR?

Are funds buying KZR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own KZR
No. of Funds

Unveiling Kezar Life Sciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
barclays plc
5.27%
3,827,356
SC 13G
Feb 14, 2024
avidity partners management lp
6.9%
5,025,454
SC 13G/A
Feb 14, 2024
orbimed advisors llc
2.7%
1,927,000
SC 13G/A
Feb 13, 2024
prosight management, lp
4.6%
3,365,333
SC 13G/A
Feb 13, 2024
suvretta capital management, llc
9.9%
7,167,591
SC 13G/A
Jan 29, 2024
blackrock inc.
6.6%
4,817,266
SC 13G/A
Jan 23, 2024
state street corp
1.54%
1,116,052
SC 13G/A
Jan 22, 2024
millennium management llc
4.0%
2,927,563
SC 13G/A
Aug 17, 2023
morningside venture investments ltd
2.68%
1,947,993
SC 13D/A
Jun 21, 2023
millennium management llc
5.2%
3,780,534
SC 13G

Recent SEC filings of Kezar Life Sciences Inc

View All Filings
Date Filed Form Type Document
Jun 04, 2024
8-K
Current Report
May 09, 2024
8-K
Current Report
May 09, 2024
10-Q
Quarterly Report
Apr 26, 2024
DEFA14A
DEFA14A
Apr 26, 2024
DEF 14A
DEF 14A
Apr 26, 2024
ARS
ARS
Apr 16, 2024
PRE 14A
PRE 14A
Mar 22, 2024
424B5
Prospectus Filed
Mar 14, 2024
S-8
Employee Benefits Plan
Mar 14, 2024
8-K
Current Report

Peers (Alternatives to Kezar Life Sciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
56.6B
6.8B
17.55% 15.42%
-9.49
8.27
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.1B
2.0B
6.10% -19.49%
-60.58
10.04
75.20% 68.82%
16.1B
2.5B
5.03% -10.77%
78.14
6.5
13.74% 186.89%
13.5B
3.8B
4.06% -3.24%
18.05
3.57
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.63% 71.22%
-9.82
48.09
54.84% -28.31%
5.2B
524.1M
-1.19% -54.45%
-12.36
9.84
394.93% 39.61%
3.4B
251.0M
-5.41% -4.45%
-11.47
13.54
73.58% -86.73%
3.2B
240.7M
16.82% -26.89%
-6.77
12.77
-1.03% -213.92%
2.5B
813.8M
1.25% -38.59%
-1.5K
3.12
56.43% 98.83%
2.2B
996.6M
20.98% 97.26%
-5.59
2.23
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-4.75% 32.39%
28.02
4.44
60.38% -34.49%
547.7M
881.7K
19.55% 492.49%
-16.22
481.06
-77.61% 33.36%
245.6M
4.2M
-16.55% 51.92%
-1.97
59.05
-66.30% 48.24%
22.0M
2.1M
40.11% 239.32%
-0.95
7.61
-13.45% 69.54%

Kezar Life Sciences Inc News

Latest updates
Business Wire07 Jun 202409:59 pm

Kezar Life Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q3
Revenue-100.0%-7,000
Operating Expenses6.3%34,58932,527
  S&GA Expenses-34.5%5,7608,789
  R&D Expenses-4.6%22,64223,738
Interest Expenses0.8%399396
Net Income-39.6%-32,260-23,103
Net Income Margin-Infinity%-14.55*-
Free Cashflow6.7%-18,981-20,341
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-10.0%19922124926328430030531825221813114015215216116813590.0098.00105113
  Current Assets-10.3%18620723124426528629931124621212513314614515416112781.0089.0096.00104
    Cash Equivalents-6.9%33.0035.0026.0028.0036.0040.0064.0010539.0063.0057.0026.0023.0021.0013.0017.0021.0015.0020.0013.0018.00
  Net PPE-6.6%4.004.004.005.005.003.003.004.003.003.003.003.003.003.004.004.004.004.005.005.005.00
Liabilities-10.9%30.0034.0033.0031.0032.0030.0022.0020.0020.0021.0011.0010.0012.0011.0011.0010.0012.0011.0011.0011.0011.00
  Current Liabilities-8.9%16.0018.0017.0014.0014.0011.0010.008.007.008.008.006.008.006.006.005.007.006.005.005.005.00
  Long Term Debt-12.3%9.0010.0010.0010.0010.0010.0010.0010.0010.0010.00-----------
    LT Debt, Current-1.00--------------------
    LT Debt, Non Current-12.3%9.0010.0010.0010.0010.0010.0010.0010.0010.0010.00-----------
Shareholder's Equity-9.8%16918821623225227028329723219711913014114115015812378.0086.0095.00102
  Retained Earnings-6.2%-372-350-318-295-271-248-230-212-196-180-166-151-139-126-115-103-94.29-84.28-74.70-65.56-56.84
  Additional Paid-In Capital0.6%542538535528524520515511430378286282280267265262217163161160159
Shares Outstanding0.0%73.0073.0073.0073.0072.0068.0072.0064.0061.0053.0052.0051.00---------
Float----173---551---252---174---119-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-20.5%-22,862-18,980-20,205-21,600-20,860-15,883-16,360-13,289-13,314-11,081-9,954-13,045-8,357-9,307-9,250-10,091-8,301-7,210-8,255-7,712-6,700
  Share Based Compensation6.6%3,4343,2206,6344,0204,2633,8173,7873,2983,1041,8531,8781,9371,9281,2801,2711,2191,1731,0071,0901,009901
Cashflow From Investing-26.8%20,40827,87818,57413,20316,391-8,661-24,7081,510-59,533-82,49138,48416,250-68717,3182,790-37,276-39,3301,67815,6232,142976
Cashflow From Financing-100.0%-59.0043.0038215450618578,32248,84899,3562,21228210,7353171,96243,99553,36880.008.001804.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

KZR Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 17,172$ 18,318
General and administrative6,5396,206
Total operating expenses23,71124,524
Loss from operations(23,711)(24,524)
Interest income2,4532,695
Interest expense(400)(370)
Net loss$ (21,658)$ (22,199)
Net loss per common share, Basic$ (0.3)$ (0.31)
Net loss per common share, Diluted$ (0.3)$ (0.31)
Weighted-average shares used to compute net loss per common share, Basic72,799,91072,328,231
Weighted-average shares used to compute net loss per common share, Diluted72,799,91072,328,231

KZR Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 33,032$ 35,493
Marketable securities146,766165,879
Prepaid expenses and other current assets5,8155,578
Total current assets185,613206,950
Property and equipment, net3,6523,912
Operating lease right-of-use asset4,3644,778
Other assets5,5015,595
Total assets199,130221,235
Current liabilities:  
Accounts payable5,0598,251
Accrued and other current liabilities6,6646,481
Operating lease liabilities, current3,1343,012
Debt, current1,3040
Total current liabilities16,16117,744
Operating lease liabilities, noncurrent5,0195,852
Debt, noncurrent8,82910,069
Total liabilities30,00933,665
Stockholders' equity:  
Common stock, $0.001 par value, 250,000,000 and 250,000,000 shares authorized as of March 31, 2024 (unaudited) and December 31, 2023, respectively; 72,801,359 and 72,779,077 shares issued and outstanding as of March 31, 2024 (unaudited) and December 31, 2023, respectively7373
Preferred stock, $0.001 par value, 10,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2024 (unaudited) and December 31, 202300
Additional paid-in capital541,824538,390
Accumulated other comprehensive loss(355)(130)
Accumulated deficit(372,421)(350,763)
Total stockholders' equity169,121187,570
Total liabilities and stockholders' equity$ 199,130$ 221,235
KZR
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEkezarlifesciences.com
 INDUSTRYBiotechnology
 EMPLOYEES84

Kezar Life Sciences Inc Frequently Asked Questions


What is the ticker symbol for Kezar Life Sciences Inc? What does KZR stand for in stocks?

KZR is the stock ticker symbol of Kezar Life Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kezar Life Sciences Inc (KZR)?

As of Wed Jun 12 2024, market cap of Kezar Life Sciences Inc is 51.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KZR stock?

You can check KZR's fair value in chart for subscribers.

What is the fair value of KZR stock?

You can check KZR's fair value in chart for subscribers. The fair value of Kezar Life Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kezar Life Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KZR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kezar Life Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether KZR is over valued or under valued. Whether Kezar Life Sciences Inc is cheap or expensive depends on the assumptions which impact Kezar Life Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KZR.

What is Kezar Life Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, KZR's PE ratio (Price to Earnings) is -0.51 and Price to Sales (PS) ratio is 7.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KZR PE ratio will change depending on the future growth rate expectations of investors.